HC Wainwright Comments on Aktis Oncology Q1 Earnings

Aktis Oncology (NASDAQ:AKTS) – Research analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Aktis Oncology in a research note issued on Tuesday, March 31st. HC Wainwright analyst R. Burns expects that the technology company will post earnings of ($0.54) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $33.00 price target on the stock. The consensus estimate for Aktis Oncology’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Aktis Oncology’s Q2 2027 earnings at ($0.57) EPS, Q3 2027 earnings at ($0.60) EPS and Q4 2027 earnings at ($0.63) EPS.

AKTS has been the topic of several other research reports. TD Cowen initiated coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They set a “buy” rating on the stock. Wall Street Zen upgraded Aktis Oncology to a “hold” rating in a research note on Saturday, January 17th. Bank of America began coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They set a “buy” rating and a $34.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 target price on the stock. Finally, Leerink Partners initiated coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 target price for the company. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $32.00.

Aktis Oncology Trading Up 8.2%

Shares of Aktis Oncology stock opened at $17.89 on Wednesday. The firm has a 50-day simple moving average of $19.19. Aktis Oncology has a 52 week low of $14.72 and a 52 week high of $29.16.

Insider Activity at Aktis Oncology

In other news, major shareholder Vida Ventures Ii, Llc acquired 835,000 shares of Aktis Oncology stock in a transaction on Monday, January 12th. The shares were acquired at an average price of $18.00 per share, with a total value of $15,030,000.00. Following the purchase, the insider directly owned 5,671,825 shares in the company, valued at $102,092,850. The trade was a 17.26% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm bought 1,112,777 shares of the stock in a transaction dated Monday, January 12th. The shares were purchased at an average price of $18.00 per share, with a total value of $20,029,986.00. Following the completion of the transaction, the insider directly owned 10,260,064 shares in the company, valued at approximately $184,681,152. The trade was a 12.17% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 6,117,776 shares of company stock valued at $110,119,968 in the last 90 days.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.